Thousands of Kiwis with ADHD are expected to benefit from Pharmac's decision to fund another medication
Thousands of Kiwis with ADHD are expected to benefit from Pharmac's decision to fund another medication
29 October 2025
Global supply disruptions have led to shortages of methylphenidate in New Zealand for the last two years.
This is expected to continue next year.
Chief Medical Officer Dr David Hughes says following public consultation, they've confirmed funding for Methylphenidate Sandoz XR - which should benefit around 3800 people in the first year.
He says this will support upcoming changes in February, when more health professionals will be able to prescribe ADHD medicines.
© 2025 Newstalk ZB, NZCity